Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Illinois EC rule challenged

This article was originally published in The Tan Sheet

Executive Summary

A lawsuit challenging the Illinois regulation that requires all pharmacists to dispense emergency contraception was filed by the D.C.-based law group American Center for Law & Justice in Springfield, Ill. District Court Dec. 19. The suit represents five Walgreens pharmacists who were indefinitely suspended or fired for refusing to prescribe EC. The Illinois regulation was introduced as an "emergency rule" by Gov. Rod Blagojevich (D) in April and signed into law in August ("The Tan Sheet" June 20, 2005, p. 11). "This regulation targets religious views and practices in an unconstitutional manner," ACLJ Senior Counsel Francis Manion states in a same-day release...

You may also be interested in...



Plan B Illinois “Emergency Rule” Challenged In Pharmacist Suit

An Illinois "emergency rule" requiring pharmacists to dispense emergency contraceptive Plan B violates the state's Health Care Right of Conscience Act, according to a suit filed in Whiteside County, Ill. court June 8

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel